Takeda Pharmaceutical Files 6-K Report
Ticker: TKPHF · Form: 6-K · Filed: May 21, 2024 · CIK: 1395064
| Field | Detail |
|---|---|
| Company | Takeda Pharmaceutical Co Ltd (TKPHF) |
| Form Type | 6-K |
| Filed Date | May 21, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, foreign-private-issuer
TL;DR
Takeda filed a 6-K, standard foreign issuer update. Nothing major to see here.
AI Summary
Takeda Pharmaceutical Company Limited filed a Form 6-K on May 21, 2024, to report information as a foreign private issuer. The filing indicates Takeda's principal executive offices are located in Tokyo, Japan, and confirms they file annual reports under Form 20-F. No specific financial transactions or material events were detailed in this particular filing.
Why It Matters
This filing serves as a routine update for investors, confirming Takeda's status as a foreign private issuer and its reporting obligations with the SEC.
Risk Assessment
Risk Level: low — This filing is a routine administrative report for a foreign private issuer and does not contain new material financial information or strategic changes.
Key Players & Entities
- Takeda Pharmaceutical Company Limited (company) — Filer of the report
- Tokyo, Japan (location) — Location of principal executive offices
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is filed by foreign private issuers to report information that they have made or are required to make public in their home country, or that they have filed or are required to file with a stock exchange on which their securities are traded.
Which form does Takeda Pharmaceutical use for its annual reports?
Takeda Pharmaceutical Company Limited indicates it files its annual reports under cover of Form 20-F.
Where are Takeda's principal executive offices located?
Takeda's principal executive offices are located at 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan.
What is the SEC file number for Takeda Pharmaceutical?
The SEC file number for Takeda Pharmaceutical Company Limited is 001-38757.
Does this 6-K filing indicate any new financial results or material events?
No, this specific Form 6-K filing does not detail new financial results or specific material events; it serves as a report of information made public in their home country or filed with a stock exchange.
Filing Stats: 386 words · 2 min read · ~1 pages · Grade level 15.5 · Accepted 2024-05-21 06:02:25
Filing Documents
- form6k_052124.htm (6-K) — 19KB
- image052124_1.jpg (GRAPHIC) — 1593KB
- image052124_2.jpg (GRAPHIC) — 1590KB
- image052124_3.jpg (GRAPHIC) — 243KB
- image052124_4.jpg (GRAPHIC) — 1591KB
- 0001395064-24-000048.txt ( ) — 6927KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. TAKEDA PHARMACEUTICAL COMPANY LIMITED Date May 21, 2024 By s Norimasa Takeda Norimasa Takeda Chief Accounting Officer and Corporate Controller Takeda Information (Correction) Partial Correction of the Summary of Financial Statements for the Fiscal Year Ended March 31, 2024 (IFRS, Consolidated) OSAKA, Japan, May 21, 2024 – Takeda (TSE4502NYSETAK) today filed with the Tokyo Stock Exchange some corrections to the consolidated financial statements (IFRS) for the fiscal year ended March 31, 2024, which was filed on May 9, 2024. Corrections are highlighted as below. There are no corrections in the "Reported" and "Core" final financial results for the fiscal year ended March 31, 2024 and XBRL data that were submitted on the same date. 1. Corrections Financial Appendix FY2023 Reconciliation from Reported to Core (page A-7) Incorrect Correct FY2023 Q4 (Jan-Mar) Reconciliation from Reported to Core (page A-8) Incorrect Correct 2. Reasons for Corrections In the reconciliation tables from Reported to Core for the full year FY2023 and Q4 FY2023 in the Financial Appendix, adjustment amounts for "Income tax (expenses) benefit" and "Net profit attributable to owners of the Company" were incorrectly presented in the column titled, "Others". There are no corrections in the "Reported" and "Core" financial results. ###